10:54 AM EDT, 06/10/2025 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Tuesday the US Food and Drug Administration has accepted the Investigational New Drug application of MRT-8102 for the treatment of certain inflammatory diseases.

The phase 1 study of MRT-8102 is expected to start in the coming weeks, with initial results anticipated in the first half of 2026, the company said.

The company said it is also working on a second-generation NEK7 program that has enhanced central nervous system penetration and plans to submit an Investigational New Drug application for it in 2026.

Shares of the company were up 4.5% in recent Tuesday trading.

Price: 5.16, Change: +0.24, Percent Change: +4.88